Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Mmmm…… delicious, cultured meat

In 2013 the first cultured meat burger was a success. You take some tissue from livestock, purify the cells, give them broth to grow on in the lab…


Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in …


Become MSc in Bioinformatics!

Next year, it will be possible to obtain an MSc in Bioinformatics at Ghent University. It is a new interdisciplinary education that joins the forc…

POPULAR TAGS

Treatment for venous malformations on its way

Written by LVS on in the category news with the tags .


Malformation of the veins is a seriously incapacitating condition and causes pain, local blood clotting and deforming lesions, which enlarge over time. These venous anomalies consist of enlarged veins with poor smooth muscle coverage and can gravely undermine quality of life. Scientists at the UCL and the de Duve Institute, in collaboration with the Harvard Medical School, have now presented their results exhibiting the first mouse model for venous malformations and a potential molecular therapy.

TIE-2 is an important receptor tyrosine kinase in blood vessel formation. In response to different molecular signals, TIE-2 is responsible for angiogenesis and vascular maturation. Hence, it isn't surprising that mutation of TIE-2 is a common cause of vascular malformations. By injecting mice with endothelial cells expressing a common human TIE-2 mutation, the investigators were able to generate the first in vivo model of venous malformation.

Additionally, the researchers demonstrated the beneficial effects of rapamycin, a complex organic compound of bacterial origin. Rapamycin significantly lowered signaling of the mutant TIE-2 and reduced the growth of lesions and vascular volume. Following these promising results, a prospective clinical study was set up comprising 6 patients refractory of standard care. Rapamycin greatly diminished pain, bleeding and impairment and drastically improved the quality of life of all included patients, making it the first possible molecular therapy for venous malformations.

Reference 

Boscolo, Elisa, et al. "Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects." The Journal of clinical investigation125.125 (9) (2015)
 

Read more about: .

RELATED ARTICLES
Mmmm…… delicious, cultured meat

In 2013 the first cultured meat burger was a success. You take some tissue from livestock, purify the cells, give them broth to grow on in the lab…


Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in …


Become MSc in Bioinformatics!

Next year, it will be possible to obtain an MSc in Bioinformatics at Ghent University. It is a new interdisciplinary education that joins the forc…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

KU Leuven V-Bio Ventures Janssen Turnstone Biowin UGent Flanders.bio XpandInnovation Itera Life Science GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.